Axitinib as an Adjuvant Treatment of Renal Cell Carcinoma Axitinib as an Adjuvant Treatment of Renal Cell Carcinoma
Does the VEGF inhibitor axitinib reduce risk of recurrence in patients with locoregional RCC post nephrectomy?Annals of Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Cancer & Oncology | Carcinoma | Health | Hematology | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma